| Name | Title | Contact Details |
|---|
Transforming cancer care with data driven medicine
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Indi Molecular provides PCCs for research and development in the fields for imaging agents for medical diagnostic imaging. Indi Imaging medical diagnostic research is provided to corporate partners, both as sponsored research or in partnership. Research and development using novel and custom PCCs, including PCCs that are membrane permeable, are provided for under the PCC Inside brand for uses that include antigen detection for both cell and tissue analysis, therapeutics or in vitro diagnostics.